Bioservo Technologies AB (publ)

MUN:10B Stock Report

Market Cap: €4.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bioservo Technologies Past Earnings Performance

Past criteria checks 0/6

Bioservo Technologies's earnings have been declining at an average annual rate of -15.8%, while the Medical Equipment industry saw earnings growing at 0.5% annually. Revenues have been declining at an average rate of 11.8% per year.

Key information

-15.8%

Earnings growth rate

9.3%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-11.8%
Return on equity-121.8%
Net Margin-395.7%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bioservo Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:10B Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2312-47470
30 Jun 2311-48490
31 Mar 2315-48520
31 Dec 2214-50540
30 Sep 2215-43480
30 Jun 2217-39440
31 Mar 2213-38410
31 Dec 2111-35360
30 Sep 217-34360
30 Jun 215-34350
31 Mar 2110-28320
31 Dec 2014-26340
30 Sep 2022-25370
30 Jun 2023-24390
31 Mar 2025-25420
31 Dec 1924-23400
30 Sep 1923-27370
30 Jun 1921-28360
31 Mar 1917-27330
31 Dec 1816-28310
30 Sep 1815-23310
30 Jun 1814-21280
31 Mar 1812-22270
31 Dec 1712-19250
30 Sep 1711-17240
30 Jun 1711-16220
31 Mar 1712-12200
31 Dec 1611-13200
31 Dec 1511-7160
31 Dec 148-4120

Quality Earnings: 10B is currently unprofitable.

Growing Profit Margin: 10B is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 10B is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.

Accelerating Growth: Unable to compare 10B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 10B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-6.1%).


Return on Equity

High ROE: 10B has a negative Return on Equity (-121.81%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/25 22:50
End of Day Share Price 2024/04/29 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioservo Technologies AB (publ) is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mats HyttingeCarlsquare AB
Mats HyttingeRedeye